Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q2

4587.TEDINET S100RNSH
Period2023-01-01 → 2023-06-30
Filed2023-08-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed

Amended by S100S6V5 (2023-11-09).

Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥9.4bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥4.5bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Revenue¥26.9bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥5.0bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.6bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Operating income−¥986m2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income−¥720m2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Operating income−¥1.7bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income−¥499m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Profit before tax−¥1.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥711m2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Profit before tax¥6.7bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥1.6bn2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥467m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Net income (owners)−¥729m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥480m2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥303m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥729m2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income−¥480m2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Net income¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income−¥303m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Total assets¥57.7bnat 2023-06-30Cons.Assets IFRS
Total assets¥63.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥52.4bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥26.7bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥31.8bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥31.0bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥24.7bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥31.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥32.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥24.7bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥11.2bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥6.4bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥8.8bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥83m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥493m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥798m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥27.4bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥26.7bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.3bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥20.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥21.6bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-5.622023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-3.72023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥58.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-8.722022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-2.332022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-5.622023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-3.72023-04-01 → 2023-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥58.142022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-8.722022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-2.332022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio53.8%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio47.0%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥30m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥30m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥30m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥228m
—segment totalrevenue2023-01-01 → 2023-06-30¥9.5bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥9.4bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥30m
—segment totalsegment profit2023-01-01 → 2023-06-30−¥941m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.4bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30¥114m
—segment totalrevenue2022-01-01 → 2022-06-30¥5.0bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥5.0bn
—segment totalsegment profit2022-01-01 → 2022-06-30−¥1.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 634
ItemContextValueUnit
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember9426049000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration9426049000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember29910000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember29910000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-29910000JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember1461366000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember7994593000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember9455959000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-29910000JPY
Revenue IFRSCurrentYTDDuration9426049000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember-1168739000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember227641000JPY
Segment profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember-941098000JPY
Segment profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Segment profit loss IFRSCurrentYTDDuration-941098000JPY
Business combination related expenses IFRSCurrentYTDDuration45000000JPY
Operating profit loss IFRSCurrentYTDDuration-986098000JPY
Finance income IFRSCurrentYTDDuration103153000JPY
Finance costs IFRSCurrentYTDDuration124756000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration-103231000JPY
Profit loss before tax IFRSCurrentYTDDuration-1110932000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-08-10
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第18期第２四半期(自 2023年４月１日 至 2023年６月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)ペプチドリーム株式会社
Company name in english cover pageFilingDateInstantPeptiDream Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長CEO 　　　　リード・パトリック
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番23号
Telephone number address of registered headquarter cover pageFilingDateInstant044(270)1300
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)ＩＲ広報部ディレクター　　沖本　優子
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番23号
Telephone number nearest place of contact cover pageFilingDateInstant044(223)6612
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)ＩＲ広報部ディレクター　　沖本　優子
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE27486
Fund codeFilingDateInstant－
Security codeFilingDateInstant45870
Filer name in japaneseFilingDateInstant
Original text (Japanese)ペプチドリーム株式会社
Filer name in englishFilingDateInstantPeptiDream Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantIFRS
Whether consolidated financial statements are preparedFilingDateInstanttrue

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass